6.09

3.57% 0.21

After Hours: 6.15 0.06 +0.99%

Insight Molecular Diagnostics Inc (IMDX)

Overview News Price History Discussions Forecast

Insight Molecular Diagnostics Inc stock is traded at $6.09, with a volume of 371.15K. It is up +3.57% in the last 24 hours and up +62.40% over the past month. Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Previous Close:

$5.88

Open:

$5.7

24h Volume:

371.15K

Relative Volume:

1.16

Market Cap:

$196.65M

Revenue:

$4.06M

Net Income/Loss:

$-50.22M

P/E Ratio:

-3.7627

EPS:

-1.6185

Net Cash Flow:

$-25.37M

1W Performance:

-4.99%

1M Performance:

+62.40%

6M Performance:

+0.83%

1Y Performance:

+0.00%

1-Day Range:

$5.43

$6.15

1-Week Range:

$5.43

$6.86

52-Week Range:

$2.33

$8.51

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name

Insight Molecular Diagnostics Inc

Sector

Healthcare (1108)

Industry

Diagnostics & Research (52)

Phone

949-409-7600

Address

2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

IMDX's Discussions on Twitter

Compare IMDX vs TMO, DHR, IDXX, WAT, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMDX Insight Molecular Diagnostics Inc	6.09	189.87M	4.06M	-50.22M	-25.37M	-1.6185
TMO Thermo Fisher Scientific Inc	448.28	167.00B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	172.00	122.68B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	559.37	43.63B	4.45B	1.10B	1.06B	13.59
WAT Waters Corp	342.37	33.48B	3.77B	449.25M	240.68M	7.8556
A Agilent Technologies Inc	114.96	32.44B	7.07B	1.29B	993.00M	4.5355

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-28-25	Initiated	Lake Street	Buy
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight
Jan-06-22	Resumed	Piper Sandler	Overweight
Mar-17-21	Resumed	Needham	Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Nov-30-20	Initiated	BTIG Research	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-02-20	Initiated	Needham	Buy
Feb-13-19	Initiated	Piper Jaffray	Overweight
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

View All

Insight Molecular Diagnostics Inc Stock (IMDX) Latest News

May 20, 2026

Earnings call transcript: Insight Molecular Diagnostics’ Q1 2026 performance and strategic outlook - Investing.com Australia

May 20, 2026

Insight Molecular Diagnostics Balances Progress and Cash Burn - TipRanks

May 20, 2026

May 17, 2026

Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha

May 17, 2026

May 15, 2026

Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail

May 15, 2026

How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance

May 15, 2026

BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Nigeria

May 15, 2026

BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com India

May 15, 2026

Insight Molecular Q1 2026 Earnings Call Transcript - Sahm

May 15, 2026

May 14, 2026

Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo

May 14, 2026